ViaLongeVita

Článek byl automaticky přeložen do zvoleného jazyka.(mymemory)

UK regulator plans to withdraw controversial vasculitis drug Tavneos over unreliable dataVIP

The Medicines and Healthcare Products Regulatory Agency (MHRA) has suspended the use and sale of Avacopan Vifor (also known as Tavneos) for new patients in the UK.Officials said that the data supporting its use were “no longer sufficiently reliable” and that “the available evidence no longer supports a positive benefit

MedScopeGlobal Editorial

September 2, 2026

This content is not medical advice, diagnosis, or treatment. Always consult your healthcare provider.

Illustration for "UK regulator plans to withdraw controversial vasculitis drug Tavneos over unreliable data" — current health topic, diverse group of adults

Enjoying this article? Support the editorial team with a tip

The Medicines and Healthcare Products Regulatory Agency (MHRA) has suspended the use and sale of Avacopan Vifor (also known as Tavneos) for new patients in the UK.Officials said that the data supporting its use were “no longer sufficiently reliable” and that “the available evidence no longer supports a positive benefit

Pro váš zájem

Tento obsah je součástí MedScope VIP

Na základě vašeho zájmu o medicínu jsme pro vás připravili plný přístup k odborným článkům, alertům a AI asistentovi.

14 dní zkušební verze zdarma — vyzkoušejte bez rizika

Odemknout předplatným

Již máte účet? Přihlásit se · Srovnání tarifů

Support the author (MedScopeGlobal Editorial) · Tip

Optional micro-contribution — like a tip. Funds ViaLongeVita editorial.

A tip is not a VIP subscription and does not unlock paid content — it is optional support for the desk.

Contribution

Donate

A micro-donation helps us keep publishing quality content.

Recommended content

Articles

Prepared by the MedScopeGlobal.com editorial team — educational health content for the public. Always consult a physician for personal medical decisions.